Table 4.

Prognostic Factors for ≧Grade 3 Adverse Effects; Univariate Analysis and Multivariate Analysis.

Prognostic Factor		All Patients (n = 150)		UVA	MVA	SBRT Alone (n = 28)		UVA	MVA	SBRT + TACE (n = 122)		UVA	MVA
		≧ Grade 3	< Grade 3	P Value	P Value	≧ Grade 3	< Grade 3	P Value	P Value	≧ Grade 3	< Grade 3	P Value	P Value
Age, years	≧75	9	64	.0524	−	1	15	.0641	−	8	49	.2027	−
	<75	19	58			4	8			15	50
Gender	Male	13	86	.0153	.0202	3	14	.9712	−	10	72	.0071	.0096
	Female	15	36			2	9			13	27
Performance status	0	26	102	.2121	−	5	16	.1543	−	21	86	.5595	−
	1 or 2	2	20			0	7			2	13
CTP class	A	20	107	.0311	.087	3	20	.1538	−	17	87	.0889	−
	B	8	15			2	3			6	12
Viral infection	HCV	18	91	.2699	−	2	16	.2111	−	16	75	.5389	−
	Non-HCV	10	31			3	7			7	24
BCLC stage	0	15	65	.9777	−	2	15	.2954	−	13	50	.603	−
	A	13	57			3	8			10	49
T stage	T1	20	93	.5951	−	4	20	.687	−	16	73	.6849	−
	T2	8	29			1	3			7	26
Greatest tumor dimensions	≧20 mm	12	51	.9188	−	3	13	.8867	−	9	38	.9472	−
	<20 mm	16	71			2	10			14	61
Tumor location	Central	4	9	.2413	−	2	2	.0698	−	2	7	.7883	−
	Periferal	24	113			3	21			21	92
Diagnosis history	Initial	10	26	.1075	−	2	11	.7505	−	8	15	.031	.3269
	Recurrence	18	96			3	12			15	84
Previous treatment (surgery)	Yes	9	52	.3086	−	3	6	.1411	−	6	46	.075	−
	No	19	70			2	17			17	53
Previous treatment (RFA/PEI)	Yes	5	36	.2122	−	1	5	.9315	−	4	31	.1836	−
	No	23	86			4	18			19	68
Mean liver dose	≧7 Gy	11	52	.7469	−	3	11	.6217	−	8	41	.5589	−
	<7 Gy	17	70			2	12			15	58
Liver V20Gy	≧10%	8	48	.2878	−	2	10	.8867	−	6	38	.2686	−
	<10%	20	74			3	13			17	61
Combination with TACE	Yes	23	99	.903	−
	No	5	23

Abbreviation: CTP, Child-Turcotte-Pugh; BCLC, Barcelona Clinic Liver Cancer; HCV, hepatitis C virus; MVA, multivariate analyses; RFA/PEI, radiofrequency ablation/ percutaneous ethanol injection; SBRT, stereotactic body radiotherapy; TACE, transcatheter arterial chemoembolization; UVA, univariate analyses; V_20Gy, percentages of uninvolved liver volume exceeding 20 Gy.